• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1280957 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type6 |2 ~+ X/ H3 @( E" _; R
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) C6 r6 E* h2 J9 A# l+ `+ Author Affiliations# e% C7 L: x- i  q: V% Q  c

% o2 M0 n- l8 q# P, B& o0 H  c0 \1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( g$ h1 T) O+ S8 ~, ~  H; f7 ?9 F2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ; L1 d+ u/ Q8 ]; v
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) ~& @* r# N; ?, A$ R# N$ n* P( w4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
0 E# i/ ]8 W- H- x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ! A3 y: G1 w. O" a7 |0 A3 J
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
- g* p* c: M  V5 ]5 F7Kinki University School of Medicine, Osaka 589-8511, Japan
- e& q- e# o# K1 f- o8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 y1 b; w4 v1 u4 i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
% a5 Z3 H9 k0 b! b# h1 m% OCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & ?- ^& Y$ n1 o
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. # ^% b4 O  C" h$ \- a4 U
" X" w1 t" f! _* t) D. m0 n! L5 P* O$ X
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
2 F! v/ j/ K8 |- V0 O
3 w6 H, y% Z' ~5 c( L' t) cAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato . i) H/ `# v4 ~; `
- V; h; [! i" N) V/ o9 z
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  2 e$ v: f; n4 J2 A) h4 C8 a  Y

: L3 }' u% V% ~; z  _* aPublished online on: Thursday, December 1, 2011 * X& B0 A8 d. ~, B- a$ d' ^
' a* g% F( W, Z' P. P( z! ?8 `
Doi: 10.3892/ol.2011.507
3 r* }  G' W% r9 L6 V6 d0 x4 E3 b: C6 @# B$ ^8 `
Pages: 405-410 9 {/ n: v* d  ], B; O8 B: ^4 N

* B: @3 C) P: y  n3 L$ {# rAbstract:
7 L* b1 j* Z7 k) AS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
: _; ]1 t- Y: W! Q4 Z
! z) r8 x1 o( X6 f8 w/ X6 r
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population# W: U7 V/ ^9 q5 b0 l
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 2 o7 P+ T. ]' m$ i4 ~8 s+ c
+ Author Affiliations( ]2 {3 W- \0 Y' A! @7 X
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
0 n8 F: [4 x- @  j3 `8 t$ c0 o5 a: |2Department of Thoracic Surgery, Kyoto University, Kyoto
) N( Y/ h+ @' y3 u% ^3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan . M5 k+ Y8 ~! ^. i. G0 n: l
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
& \/ q4 B+ |/ z% g3 T, P! yReceived September 3, 2010. $ C7 b# J) _  y1 }0 \4 e
Revision received November 11, 2010.
; s8 N1 I* Z0 v- i; cAccepted November 17, 2010. ' n( B9 t# r! I6 Z3 P+ q! {
Abstract
6 l3 q" ?: A) x/ l! J( zBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
) I5 z8 o  S2 v1 x, \- Z9 G. k9 {' xPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
7 x( H8 @% A& t& C$ |9 `, }Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 0 a" n5 ^# E+ _: H
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
+ j' q) k0 k( ~; ?/ w
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
7 U  [9 r( }* l. t" p7 Z3 E3 B今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
. X3 y6 P4 ~  Y+ e
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy4 o( W! [0 S# P7 d# h
http://clinicaltrials.gov/ct2/show/NCT01523587" ?/ O, ^8 v& o6 P% y; C- z0 k
$ |7 t1 k9 C# B1 [4 j
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC3 O- v5 m# j8 w) [+ ]
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
& p, f5 X$ G$ h1 r8 {# h3 j! p) x' a+ ?8 R
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。0 t' y- I' C2 h
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

9 ]  O9 f0 q# c没有副作用是第一追求,效果显著是第二追求。
* |2 p1 k% x5 B不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表